TPWA
NBIX icon

TRUE Private Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

TRUE Private Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,033
Closed -$127K – 673
2018
Q3 		$127K Buy
+1,033
New +$117K 0.02% 317

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TRUE Private Wealth Advisors's NBIX Position: Q4 2018 in Review

TRUE Private Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 1,033 shares — an estimated $127K sold.

TRUE Private Wealth Advisors first reported a position in NBIX in Q3 2018 and held it in 1 quarter. The position peaked at $127K in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • TRUE Private Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • TRUE Private Wealth Advisors sold 1,033 Neurocrine Biosciences shares in Q4 2018, an estimated $127K.
  • TRUE Private Wealth Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 1 quarter.
  • TRUE Private Wealth Advisors's Neurocrine Biosciences position peaked at $127K in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on TRUE Private Wealth Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.